Zura CEO States Strong Financial Position Ahead of Tibulizumab Readouts
"We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing conviction in bispecific approaches and increased appreciation for IL-17 and BAFF biology" said Sandeep Kulkarni, M.D., Chief Executive Officer of Zura. "We believe we are well positioned-operationally, financially, and scientifically-as we approach anticipated tibulizumab readouts starting later this year."
